Phase I Clinical Study Using an Antifibrotic Drug

使用抗纤维化药物的 I 期临床研究

• 批准号: 8136803
• 负责人: WEIZHONG CAI
• 金额: $ 76.46万
• 依托单位: ANGION BIOMEDICA CORPORATION
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-03-01 至 2013-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8136803
• 关键词: Acute; Affect; Alcohol consumption; Antiviral Agents; Applications Grants; Biological Assay; Businesses; Cells; Cessation of life; Chronic; Cicatrix; Cirrhosis; Clinic; Clinical; Clinical Research; Clinical Trials; Consult; Data; Development; Dialysis patients; Disease; Doctor of Medicine; Doctor of Philosophy; Dose; Double-Blind Method; Drug Formulations; Drug Kinetics; Enrollment; Epidemic; Extrahepatic; Fibrosis; Funding; Genes; Grant; Growth Factor; Half-Life; Hepatic; Hepatitis B; Hepatitis C; Hepatocyte Growth Factor; Human; Immune response; Incidence; Inflammatory Response; Injury; Intravenous; Iron Overload; Leadership; Liver; Liver Cirrhosis; Liver Failure; Liver Fibrosis; Liver diseases; Medical center; Obstruction; Oral; Oral Administration; Patients; Personnel Staffing; Pharmaceutical Preparations; Pharmacists; Phase; Phase I Clinical Trials; Placebo Control; Placebos; Population Study; Positioning Attribute; Program Development; Proteins; Randomized; Renal dialysis; Research; Research Design; Research Project Grants; Safety; Serum; Solutions; Specific qualifier value; Testing; Tissues; Toxicology; Translational Research; United States National Institutes of Health; Virus Diseases; cohort; cost; experience; healthy volunteer; innovation; liver transplantation; meetings; mimetics; nonalcoholic steatohepatitis; novel; phase 1 study; pre-clinical; programs; public health relevance; regenerative; response; small molecule

DESCRIPTION (provided by applicant): Liver fibrosis, a disease affecting tens of millions of people worldwide, is the liver scarring response to chronic injury from excessive alcohol use, virus infection (hepatitis B and C), iron overload or extrahepatic obstructions and can progress to liver cirrhosis, liver failure and death. In fact, deaths from complications of liver fibrosis/cirrhosis are expected to triple over the next decade as a result of the hepatitis C epidemic and the growing incidence of liver disease associated with non-alcoholic steatohepatitis. Currently available therapies, including antivirals, are largely ineffective in treating the underlying fibrosis, and in the majority of cases, liver transplantation is the only effective cure. Hepatic growth factor (HGF), also known as scatter factor (SF), has been shown to be efficacious in reducing liver fibrosis. The feasibility of HGF as gene or protein therapy however is limited by issues relating to immune and inflammatory responses evoked by adenoviral proteins, inherent instability of proteins in solution, their limited tissue half-life, and the exorbitant costs associated with such therapy. Supported by the National Institutes of Health (NIH) Small Business Innovative Research (SBIR) and Rapid Access to Interventional Development (RAID) programs, we have identified and developed BB3, a novel small molecule HGF mimetic. BB3 duplicates the bioactivities of HGF in every assay tested to date. Particularly, BB3 possesses cell protective, anti-fibrotic, and regenerative activities and shows efficacy in reducing liver fibrosis. The overall objective of our program is to advance BB3 to the clinic as a first-in-class antifibrotic for liver fibrosis. From a clinical perspective, a Phase I safety and pharmacokinetic (PK) trial of intravenously administered BB3 has been completed successfully in healthy volunteers and BB3 was found to be well tolerated. In addition, a clinical study of intravenously administered BB3 for safety and PK in renal dialysis patients has been completed. While intravenous BB3 is being developed for acute indications, we are also developing oral BB3 for chronic indications. In this fast-track SBIR grant application, we propose to conduct a Phase 1 clinical study evaluating safety and PK of BB3 administered orally in healthy volunteers. PUBLIC HEALTH RELEVANCE: A small-molecule, hepatically protective and anti-fibrotic agent has significant clinical potential against both liver fibrosis.

描述（由申请人提供）：肝纤维化是一种影响全球数千万人的疾病，是对过度饮酒、病毒感染（B肝炎和丙型肝炎）、铁过载或肝外梗阻引起的慢性损伤的肝脏瘢痕形成反应，可进展为肝硬化、肝功能衰竭和死亡。事实上，由于丙型肝炎的流行和与非酒精性脂肪性肝炎相关的肝病发病率的增加，预计未来十年肝纤维化/肝硬化并发症的死亡人数将增加两倍。目前可用的疗法，包括抗病毒药物，在治疗潜在的纤维化方面基本无效，并且在大多数情况下，肝移植是唯一有效的治愈方法。肝生长因子（HGF），也称为分散因子（SF），已被证明可有效减少肝纤维化。然而，HGF作为基因或蛋白质治疗的可行性受到与腺病毒蛋白引起的免疫和炎症反应、蛋白质在溶液中的固有不稳定性、它们有限的组织半衰期以及与这种治疗相关的过高成本有关的问题的限制。在美国国立卫生研究院（NIH）小企业创新研究（SBIR）和快速介入发展（RAID）计划的支持下，我们鉴定并开发了一种新型小分子HGF模拟物BB 3。BB 3在迄今为止测试的每个测定中重复HGF的生物活性。特别地，BB 3具有细胞保护、抗纤维化和再生活性，并显示出减少肝纤维化的功效。我们项目的总体目标是将BB 3作为一流的抗肝纤维化药物推向临床。从临床角度来看，静脉内施用BB 3的I期安全性和药代动力学（PK）试验已经在健康志愿者中成功完成，并且发现BB 3耐受良好。此外，已经完成了在肾透析患者中静脉施用BB 3的安全性和PK的临床研究。虽然静脉注射BB 3正在开发用于急性适应症，但我们也在开发用于慢性适应症的口服BB 3。在这项快速SBIR拨款申请中，我们计划进行一项1期临床研究，评估健康志愿者口服BB 3的安全性和PK。 公共卫生关系：一种小分子的肝脏保护和抗纤维化药物具有显著的临床潜力，可以对抗肝纤维化和肝纤维化。